retatrutide dose clinical trials trial dosing frequency microdosing: guide to split protocols and schedules The Retatrutide Dosage Chart: A – Retatrutide Explained: How It Works,

2030 (USD BILLION) FIGURE 16 REGIONAL SNAPSHOT OF GLP-1 AGONISTS MARKET FIGURE 17 INCREASING PREVALENCE OF TYPE-2 DIABETES AND OBESITY TO PROPEL MARKET GROWTH FIGURE 18 US AND DIABETES DOMINATED NORTH AMERICAN MARKET IN 2024 FIGURE 19 SINGLE-DOSE FORMATS ACCOUNTED FOR LARGEST GLP-1 AGONISTS FORMAT MARKET SHARE IN 2024 FIGURE 20 HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 FIGURE 21 KINGDOM OF SAUDI ARABIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD FIGURE 22 GLP-1 AGONISTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FIGURE 23 US: PREVALENCE OF INDICATIONS THAT RESPOND TO GLP-1 DRUGS (AS OF JANUARY 2024) FIGURE 24 GLP-1 AGONISTS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS BUSINESSES FIGURE 25 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 20222024 (USD) FIGURE 26 GLP-1 AGONISTS MARKET: VALUE CHAIN ANALYSIS FIGURE 27 GLP-1 AGONISTS MARKET: ECOSYSTEM ANALYSIS FIGURE 28 GLP-1 AGONISTS MARKET: PORTERS FIVE FORCES ANALYSIS FIGURE 29 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF GLP-1 AGONISTS, BY TYPE FIGURE 30 KEY BUYING CRITERIA FOR END USERS FIGURE 31 AI USE CASES IN GLP-1 AGONISTS MARKET FIGURE 32 NORTH AMERICA: GLP-1 AGONISTS MARKET SNAPSHOT FIGURE 33 ASIA PACIFIC: GLP-1 AGONISTS MARKET SNAPSHOT FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN GLP-1 AGONISTS MARKET, 20202024 (USD BILLION) FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN GLP-1 AGONISTS MARKET (2024) FIGURE 36 GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 FIGURE 37 GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX (PLAYERS WITH PRODUCTS IN PIPELINE), 2024 FIGURE 38 GLP-1 AGONISTS MARKET: COMPANY FOOTPRINT (KEY PLAYERS) FIGURE 39 GLP-1 AGONISTS MARKET: COMPANY FOOTPRINT (PRODUCTS IN PIPELINE) FIGURE 40 GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 FIGURE 41 EV/EBITDA OF KEY VENDORS FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS FIGURE 43 GLP-1 AGONISTS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS FIGURE 44 NOVO NORDISK A/S: COMPANY SNAPSHOT FIGURE 45 ELI LILLY AND COMPANY: COMPANY SNAPSHOT FIGURE 46 SANOFI: COMPANY SNAPSHOT FIGURE 47 HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED: COMPANY SNAPSHOT FIGURE 48 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT FIGURE 49 INNOVENT: COMPANY SNAPSHOT FIGURE 50 ZEALAND PHARMA: COMPANY SNAPSHOT FIGURE 51 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT FIGURE 52 AMGEN INC.: COMPANY SNAPSHOT FIGURE 53 GLENMARK PHARMACEUTICALS LTD.: COMPANY SNAPSHOT FIGURE 54 BIOCON: COMPANY SNAPSHOT FIGURE 55 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT FIGURE 56 F

2022;119(13):e2116506119

Its also the first medication approved to help treat moderate-to-severe obstructive sleep apnea in adults with obesity, highlighting how these treatments may impact far more than the number on the scale

Recovery capacity is reduced when calories are significantly lower

The medication Mounjaro is used in the treatment of type 2 diabetes to lower blood glucose levels (sugar levels)